Using a Data Catalog to Support Precision Medicine

Using a Data Catalog to Support Precision Medicine

Publication date: Jan 14, 2020

In the first story of this series, we made the case for applying common data governance (DG) and tools in organizations to help with the quality and privacy of consumer data.

To have the best chances of success, we suggested in a second story that organizations should wage the battle for a single source of reference of their data assets through a governed, global data catalog.

This recent study, developed by UK scientists at Cambridge, is the first to combine non-genetic factors (e. g., clinical data, lifestyle) with known genetic ones in a risk prediction model for breast cancer.

Nongenetic RFs in the model are classified as: At a high level, our data scientists must build a pipeline to find, for each patient, the following data: In the scenario above, our data scientists can rely on existing data assets, but need others.

The DG organization has defined the following policies for such data: The data catalog helps during the governance requirements phase as follows.

In this blog series we have striven to demonstrate that large organizations, which generally have no single source of truth for decision making, must introduce data governance processes to address the challenges of locating trustworthy data and analytic assets to help develop, inform and influence business initiatives -the definition of an organization being data-driven.

This blog has shown that a data catalog is a key technology ingredient in supporting DG, including privacy regulations such as GDPR.

Concepts Keywords
Alcohol Privacy law
Analytic Information privacy
Automation Law
Breast Internet privacy
Breast Cancer In Europe
Business Objects Data protection
Cambridge Data security
Cancer Technology proper governance
Coronary Artery
Relative Risk


Type Source Name
disease MESH literacy
drug DRUGBANK Ethanol
disease MESH mammographic density
disease MESH risk factors
disease MESH multiple
disease MESH privacy
drug DRUGBANK Spinosad
disease MESH lifestyle
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH cancer
disease MESH coronary artery disease


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *